Clinical Insights 1 min read

The Glomerular Revolution – What Sponsors Must Do Next to Win in Rare Renal Disease

Authors:Jonathan Barratt, PhD, FRCP. The Mayer Professor of Renal Medicine at University of Leicester, Claudio Hegenberger, MD. Vice President, Scientific and Medical Affairs, Emerald Clinical

For decades, rare glomerular diseases sat at the margins of drug development. Despite devastating lifelong consequences for young patients, conditions such as IgA nephropathy (IgAN), membranous nephropathy (MN), focal segmental glomerulosclerosis (FSGS), and C3 glomerulopathy (C3G) were widely viewed as scientifically complex, operationally risky, and commercially uncertain. Clinical trials were slow, endpoints were misaligned with disease biology, and sponsors struggled to demonstrate value to regulators and payers.

That era is ending with the advent of the “glomerular revolution.”

To read the full article please fill out the form below.

First name *

Email *

Country *

Last name *

Job title *

Phone number

Company name *

Terms agreement *

I agree to the handling of my personal information in accordance with the Emerald Clinical privacy policy.

Message